But her case is caused by a rare genetic mutation, so medications that work for 90% of people with cystic fibrosis won't help her. The same dynamic plays out in other genetic conditions.

People with diseases caused by rare mutations have fewer options and poorer prospects than other patients despite rapid recent advancements in the growing field of genetic science Emily Kramer ...

“When it’s you at stake, that’s nowhere near as powerful as people you really really love,” he adds. And in the process of training, Wetherill has become “addicted” to pushing his ...

Warburg Research analyst Hannes Müller maintained a Buy rating on cyan AG (CYR – Research Report) on April 2 and set a price target of €4.00. The company’s shares closed yesterday at €2.96.